News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Alper Topal: The Keynote 921 study failed for CRPC
Alper Topal/researchgate.net
Mar 18, 2025, 12:35

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:

“The Keynote 921 study failed for CRPC.

mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Authors: Daniel P. Petrylak et al.

Alper Topal

Alper Topal Andrew J. Armstrong Andries M. Bergman cancer Charles Schloss Christian H. Poehlein Daniel P. Petrylak Eric Levesque Ernesto Korbenfeld Gero Kramer Howard Gurney Karim Fizazi Loic Mourey Margitta Retz Maria De Santis Meital Levartovsky Nobuaki Matsubara OncoDaily Oncology Pawel Zalewski Raffaele Ratta Ray Manneh Ray McDermott Russell Pachynski Rustem Gafanov Seok Soo Byun Sergio Bracarda Tilman Todenhofer Winald Gerritsen Xin Tong Li
Special Coverage
Career
May 9, 2025, 07:02
Vinay Prasad Appointed as the New Head of FDA's Center for Biologics Evaluation and Research
Blog
May 9, 2025, 06:47
Wade Swenson: Addressing the rural cancer care crisis in Minnesota requires innovative solutions
Oncolibrary
May 9, 2025, 06:27
Understanding Neoplasms: What They Are, Types, Causes, and How They’re Treated
Insight
May 9, 2025, 06:07
Oguna Kasam: Landmark Achievement for Kenya - Aga Khan University Hospital Delivered First Lutetium 177 Therapy
Drugs
May 9, 2025, 05:39
Erika Hamilton: Zanidatamab Combination Shows Promising Results in HR+/HER2+ Metastatic Breast Cancer
Science
May 9, 2025, 04:20
Valerie Yang: What started out as an academic collaboration is now available as a treatment option for soft tissue sarcoma patients
Cancer Types
May 9, 2025, 02:44
Medulloblastoma: Breakthroughs in Types, Symptoms, Diagnosis, Treatment, and 2025 Advances in Care
Blog
May 9, 2025, 01:36
Laura Bukavina: We walk to fuel research and hope
Blog
May 8, 2025, 18:13
Highlights from the NCCN Oncology Policy Summit 2025
Opinion
May 8, 2025, 18:12
Erman Akkus highlights new platinum derivatives Aurkine 16 and 18 for cancer treatment
Career
May 8, 2025, 18:06
Wafik S. El-Deiry congratulated Brooke Verschleiser on winning 2025 Llealyn B. Clapp Prize at the Brown University
Career
May 8, 2025, 18:00
E. John Wherry elected to National Academy of Sciences for cancer immunotherapy research